CBX1 (p25beta) as a Potential Drug Target and Biomarker for Cancer: An Overview

Target Name: CBX1

NCBI ID: G10951

CBX1

CBX1 (p25beta) as a Potential Drug Target and Biomarker for Cancer: An Overview

Abstract:

CBX1 (p25beta), a 25kDa hydrophobic ribonuclease, is involved in cell cycle-specific regulation of the degradation of nucleolin (p25). In various cancers, the expression level of CBX1 changes and is closely related to disease prognosis and treatment response. This article aims to explore the role of CBX1 in cancer as a potential drug target or tumor biomarker.

1 Introduction

2. Discovery and identification of CBX1

2.1 Overview of CBX1

2.2 Expression and regulation of CBX1

2.3 Clinical significance of CBX1

3. Mechanism of action of CBX1

3.1 CBX1 is involved in cell cycle regulation

3.2 Relationship between CBX1 and p25

3.3 The role of CBX1 in tumors

4. Possibility of CBX1 as a drug target

4.1 Advantages of CBX1 as an anti-tumor drug target

4.2 Challenges of CBX1 as an anti-tumor drug target

4.3 Combination strategies of CBX1 and targeted therapy

5. Application of CBX1 as a tumor biomarker

5.1 CBX1 as a biomarker for early diagnosis of tumors

5.2 CBX1 as a biomarker for tumor prognosis assessment

5.3 Biomarker research on CBX1 and tumor treatment

6 Conclusion

Protein Name: Chromobox 1

Functions: Component of heterochromatin. Recognizes and binds histone H3 tails methylated at 'Lys-9', leading to epigenetic repression. Interaction with lamin B receptor (LBR) can contribute to the association of the heterochromatin with the inner nuclear membrane

The "CBX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets